Dalan Animal Health
Dalan Animal Health is a biotechnology company that has developed the world's first USDA-approved vaccine for honeybees and is extending its Transgenerational Immune Priming platform to shrimp aquaculture, serving commercial and hobbyist beekeepers and the global $45B shrimp industry.
- Company typePrivate
- Founded2018
- HeadquartersAthens, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dalan Animal Health does
Dalan Animal Health is a privately held biotechnology company founded in 2018 and headquartered in Athens, Georgia, that develops vaccines for invertebrate species using its proprietary Innate Immunity Platform. Its lead product is the world's first USDA-conditionally licensed vaccine for honeybees, a killed Paenibacillus larvae bacterin that protects against American Foulbrood. The vaccine is administered orally to queen bees via queen candy, and immunity is transferred to offspring through Transgenerational Immune Priming (TGIP), a mechanism in which inactivated bacteria are transported via vitellogenin protein to the ovaries and deposited in eggs, priming larvae before they hatch. The company has also extended the platform to a first-in-class shrimp vaccine in development targeting White Spot Syndrome Virus and Early Mortality Syndrome for the $45 billion global shrimp aquaculture industry, with a strategic partnership with INVE (January 2026) supporting global aquaculture distribution.
The commercial model combines direct sales to large commercial beekeepers (quote-based for orders covering >50 hives) with a retail partner network across the USA and Canada including Mann Lake, Dadant, Honey Bee Genetics, Woodcamp Farm, and Dancing Bee Equipment. Partners sell both the vaccine and vaccinated queen bees and package bees, with vaccinated queens carrying approximately a $10 retail premium. Veterinary distribution serves as an additional channel, particularly in Canada where CFIA regulations require veterinary prescription. The company has demonstrated commercial traction with 20,000+ hives vaccinated and reports of 30–50% reduction in larval mortality, 83% effectiveness against Deformed Wing Virus-B, and 90% lower DWV-B viral loads in vaccinated colonies.
Across four disclosed funding rounds plus the December 2025 Yuyu Pharma strategic investment, Dalan has raised approximately $12.3M from Prime Movers Lab, At One Ventures, Good Growth Capital, Meach Cove Capital, and other backers. The company holds a USPTO Notice of Allowance on its foundational edible-vaccination patent, regulatory approvals in the US (conditional) and Canada (full market authorization), and European market entry underway via a subsidiary that secured a €250K pan-European surveillance grant. Recognition includes TIME Best Inventions 2023, Fast Company Next Big Thing in Tech 2023, the George Washington Carver Award (2024), and the TCRS Innovation Award (2025). Headcount sits in the 11–50 range, consistent with early commercial-stage operations.
Dalan Animal Health firmographics
Firmographics- Name
- Dalan Animal Health
- Legal name
- Dalan Animal Health, Inc.
- Website
- https://dalan.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Dalan Animal Health is a biotechnology company that has developed the world's first USDA-approved vaccine for honeybees and is extending its Transgenerational Immune Priming platform to shrimp aquaculture, serving commercial and hobbyist beekeepers and the global $45B shrimp industry.
- Ownership category
- akta.pro rank
Dalan Animal Health industry classification
Industry- Product category
- Veterinary Biologics and Animal Health Vaccines
- NAICS
- Veterinary Services (541940)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Wildlife & Zoo/Exotic Animal Vaccines (HLAMAKAG)
- akta.pro secondary industries
- Aquaculture/Fish & Shrimp Vaccines (HLAMAKAE), Veterinary Vaccines (HLAIAEAH)
Keywords
Where Dalan Animal Health is headquartered
LocationHeadquarters
- HQ city
- Athens
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Dalan Animal Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- Honeybee Vaccine Sales: Dalan sells its Paenibacillus larvae bacterin vaccine directly to beekeepers and through retail partners. The product is sold as 50-dose vials, with minimum orders of 50 doses. Commercial beekeepers with >50 hives can request quotes directly from the company. The vaccine provides a prophylactic, sustainable alternative to antibiotics for American Foulbrood prevention.
- Vaccinated Queen and Package Sales: Dalan distributes vaccinated queen bees and package bees through certified partner retailers. Vaccinated queens command a premium price, typically $10 markup compared to non-vaccinated queens. Partners include Mann Lake, Honey Bee Genetics, Woodcamp Farm, Dancing Bee Equipment, Dadant, and others across the USA and Canada.
- Shrimp Vaccine (Development Stage): The company is developing a first-in-class shrimp vaccine targeting White Spot Syndrome Virus (WSSV) and Early Mortality Syndrome (EMS) for the $45 billion global shrimp industry. The $3M SAFE funding round (November 2025) is specifically supporting commercialization efforts, regulatory approval, manufacturing scale-up, and market development for this product.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Vaccine product - 50 dose minimum order |
| Unit Pricing | Pay-as-you-go | Vaccinated queens - retail markup |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
Dalan Animal Health product offering
Product offeringCore offering
Dalan Animal Health develops and commercializes biological vaccines for invertebrate species that lack adaptive immune systems, using a proprietary Transgenerational Immune Priming (TGIP) platform. Its flagship commercial product is the world's first USDA-approved vaccine for honeybees, protecting against American Foulbrood disease, and it is extending the platform into aquaculture with a first-in-class shrimp vaccine targeting White Spot Syndrome Virus and Early Mortality Syndrome.
Product overview
Dalan Animal Health is a biotechnology company that has developed an Innate Immunity Platform technology enabling vaccine development for invertebrate species. The company's portfolio consists of two core products: the Honeybee Vaccine (Paenibacillus Larvae Bacterin), which is the world's first USDA-conditionally licensed vaccine for an insect species protecting against American Foulbrood disease, and the Shrimp Vaccine, a first-in-class vaccine in development targeting White Spot Syndrome Virus (WSSV) and Early Mortality Syndrome (EMS) for the $45 billion global shrimp industry. Both products utilize transgenerational immune priming (TGIP) technology, where vaccines are administered to maternal animals and immunity is passed to offspring before hatching. The platform has potential applications across other aquaculture species and poultry.
Differentiator
Problem solved
Functional benefit
Products and services
- Honeybee Vaccine (Paenibacillus Larvae Bacterin) The world's first USDA-conditionally licensed vaccine for honeybees, protecting against American Foulbrood disease caused by Paenibacillus larvae. Administered orally to queen bees via queen candy (one 3ml 50-dose vial mixed with 300g candy; 6g administered per queen cage), with immunity passed to offspring through Transgenerational Immune Priming (TGIP). Non-GMO, contains no chemicals or harmful preservatives, and is suitable for organic agriculture. Sold to commercial beekeepers (>50 hives) via direct quote-based sales and to smaller beekeepers via pre-order of vaccinated queens and packages through retail partner network (Mann Lake, Dadant, Honey Bee Genetics, Dancing Bee Equipment, etc.) in the USA and Canada.
- Vaccinated Queen Bees and Package Bees Live queen bees and package bees that have been vaccinated using Dalan's Paenibacillus larvae bacterin vaccine, distributed through certified partner retailers including Mann Lake (California and Kentucky), Honey Bee Genetics (California), Woodcamp Farm (Maryland), Dancing Bee Equipment (Canada), Dadant (USA), White Mountain Apiary (New Hampshire), Heitkams' Honey Bees (California), Can-Am Apiaries (California), Brawes Bee Farm (North Carolina), Meyer Bees (Illinois), Foley's Russian Bees (Iowa), and Buzz's Bees (California). Vaccinated queens command approximately a $10 premium per queen compared to non-vaccinated queens and offer built-in American Foulbrood resistance to downstream beekeeping customers.
Quantifiable outcome
- 30-50% reduction in larval mortality from American Foulbrood
- +4 more outcomes
Companies that use Dalan Animal Health
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
Dalan Animal Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Dalan Animal Health partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- INVE (part of the SHIC network)coreStrategic partnership to advance shrimp disease prevention through vaccination strategies and scalable solutions. Dalan and INVE are joining forces to strengthen shrimp health and sustainability worldwide, leveraging Dalan's vaccine technology with INVE's aquaculture expertise and distribution network.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Dalan Animal Health competitors and assessment
Company assessmentBroad incumbents
- Ceva Animal Health: Top-5 global animal health company and leading veterinary biologics manufacturer. Directly comparable because Dalan's CSO Erin Strait was previously Director of Innovation at Ceva, and Ceva operates in poultry, swine, and aquaculture vaccines — overlapping with Dalan's pipeline and current platform focus.
- Zoetis: Largest pure-play animal health company globally, with leading vaccine franchises across livestock and companion animals. Comparable as the dominant animal biologics incumbent; Dalan board member Linda Rhodes sits on Zoetis's board, underscoring how closely Dalan competes for the same biologics innovation space.
- Merck Animal Health: Division of Merck operating one of the world's broadest veterinary vaccine portfolios. Comparable as a major animal-vaccine incumbent; Dalan's CSO previously led U.S. Swine Biologics discovery at Merck Animal Health, evidencing direct technical overlap and competition for talent and customers.
- Boehringer Ingelheim Animal Health: Global top-3 animal health company with leading swine, poultry, and aquaculture vaccine franchises. Comparable because Dalan's Nigel Swift previously led global vaccine R&D at BI following its Merial acquisition, making BI a direct incumbent competing for similar species and aquaculture customers.
- Elanco Animal Health: Large-cap pure-play animal health company with vaccine and therapeutic portfolios across species. Comparable as a broad incumbent in animal biologics competing for the same disease-prevention budgets across livestock, aquaculture, and companion animals.
- Vetoquinol: Mid-to-large animal health company with biologics and pharmaceutical portfolios across livestock and companion animals. Comparable as another broad incumbent developing vaccines for production animals, directly overlapping with Dalan's pipeline ambition.
- Phibro Animal Health: Animal health company with vaccines, nutritional specialties, and aquaculture health products. Comparable as an incumbent with overlapping aquaculture health and livestock vaccine portfolios targeting many of the same species and disease problems as Dalan's platform.
- Virbac: Global animal health company with strong biologics and vaccine portfolio across species. Comparable as a broad incumbent in veterinary vaccines and aquaculture health, competing for the same innovation and customer relationships Dalan seeks to enter.
Direct peers
- HIPRA: Spanish veterinary biologics company specializing in vaccines for livestock and aquaculture. Most comparable as a similarly-sized specialist vaccine developer with strong R&D focus, competing for the same species-vaccine customers Dalan is targeting with its platform.
- INVE (Benchmark Holdings): Leading aquaculture health and nutrition company and Dalan's January 2026 strategic partner for the shrimp vaccine. Comparable as both a collaborator and adjacent aquaculture-health competitor with deep shrimp-farmer relationships that determine market access for Dalan's shrimp product.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Dalan Animal Health social profiles
Digital presenceDalan Animal Health compliance and trust
Trust signalCompliance3 records
Dalan Animal Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dalan Animal Health leadership team
Management profileNumber of profiles
Profiles11 records
Dalan Animal Health subsidiaries and ownership
Company hierarchySubsidiaries1 record
Dalan Animal Health funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dalan Animal Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dalan Animal Health
What does Dalan Animal Health do?
Dalan Animal Health develops and commercializes biological vaccines for invertebrate species that lack adaptive immune systems, using a proprietary Transgenerational Immune Priming (TGIP) platform. Its flagship commercial product is the world's first USDA-approved vaccine for honeybees, protecting against American Foulbrood disease, and it is extending the platform into aquaculture with a first-in-class shrimp vaccine targeting White Spot Syndrome Virus and Early Mortality Syndrome.
Is Dalan Animal Health a public or private company?
Dalan Animal Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Dalan Animal Health founded?
Dalan Animal Health was founded in 2018. It employs 11 to 50 people.
Where is Dalan Animal Health based?
Dalan Animal Health is headquartered in Athens, United States, in the North America region.
How does Dalan Animal Health make money?
Three revenue lines are on record. Honeybee Vaccine Sales are the primary driver. The others are vaccinated Queen and Package Sales and shrimp Vaccine (Development Stage).
Who are Dalan Animal Health's main competitors?
Broad incumbents on record are Ceva Animal Health, Zoetis, Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health, Vetoquinol, Phibro Animal Health and Virbac. Direct peers are HIPRA and INVE (Benchmark Holdings).
Does Dalan Animal Health have an API?
No public API is recorded for Dalan Animal Health.
What industry is Dalan Animal Health in?
Dalan Animal Health's product category is Veterinary Biologics and Animal Health Vaccines. Its primary akta.pro industry code is HLAMAKAG, Wildlife & Zoo/Exotic Animal Vaccines, with a secondary code of HLAMAKAE, Aquaculture/Fish & Shrimp Vaccines. Its NAICS code is 541940 and its SIC code is 2836.